Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Free Cash Flow (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Free Cash Flow for 16 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 3590.55% to $10.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.5 million, a 551.39% increase, with the full-year FY2025 number at $10.5 million, up 551.39% from a year prior.
  • Free Cash Flow was $10.1 million for Q4 2025 at Anika Therapeutics, up from $1.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $10.1 million in Q4 2025 to a low of -$10.4 million in Q2 2023.
  • A 5-year average of $682950.0 and a median of $646500.0 in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 1006.79% in 2023, then soared 3590.55% in 2025.
  • Anika Therapeutics' Free Cash Flow stood at $8.5 million in 2021, then crashed by 37.09% to $5.3 million in 2022, then crashed by 119.51% to -$1.0 million in 2023, then skyrocketed by 126.44% to $275000.0 in 2024, then skyrocketed by 3590.55% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Free Cash Flow are $10.1 million (Q4 2025), $1.5 million (Q3 2025), and $1.8 million (Q2 2025).